跳至主要内容
临床试验/NCT00680095
NCT00680095已完成1 期

21-day Cumulative Irritation Test

Pfizer1 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2007年1月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
37
试验地点
1
主要终点
Severe irritation (Grade 3 or 4) observed at any site

研究概览

简要总结

The purpose of this study is to determine the cumulative irritation potential of the products listed by the Sponsor.

详细描述

Healthy, adult volunteers of either sex will be patched on his/her back with AN2690 Solution 2.5%, AN2690 Solution 5%, AN2690 Solution 7.5%, AN2690 Solution Vehicle and Sodium Laurel Sulfate 0.5% over the course of 21 consecutive days. After 24 hours, the patches are to be removed and the site evaluated using a five-point scale for irritation.

研究设计

研究类型
Interventional
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy, volunteers of either sex, at least 18 years of age or older
  • Females of childbearing potential submitted to a urine pregnancy test and had negative results at Day 1 and at the final visit and also was using an effective method of birth control (e.g. abstinence, implants, injectables, oral contraceptives, intrauterine contraceptive devices or double barrier) or agreed to use an effective method of birth control prior to becoming sexual active
  • Subjects were of any skin type or race providing their degree of pigmentation did not interfere with making readings of skin reactions
  • Subjects were willing to follow the study procedures and complete the study
  • Written informed consent was obtained

排除标准

  • Subject with any skin disease that would have in any way confounded interpretation of the study results. Atopic dermatitis/eczema, psoriasis or chronic asthma were excluded
  • Subject was pregnant or nursing
  • Subject had a history of sensitivity to any component of any of the formulations
  • Use of chronic medications (such as antihistamines, corticosteroids, analgesics and anti-inflammatories) for one week before and during the study

研究组 & 干预措施

A

Experimental

AN2690 Solution, 2.5%

干预措施: AN2690 (Drug)

B

Experimental

AN2690 Solution, 7.5%

干预措施: AN2690 (Drug)

C

Experimental

AN2690 Solution, 5.0%

干预措施: AN2690 (Drug)

D

Active Comparator

AN2690 Solution, Vehicle

干预措施: AN2690 Solution, Vehicle (Other)

E

Active Comparator

Sodium Lauryl Sulfate, 0.5%

干预措施: Sodium Lauryl Sulfate, 0.5% (Other)

结局指标

主要结局

Severe irritation (Grade 3 or 4) observed at any site

时间窗: Daily for 21 days

次要结局

未报告次要终点

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验